Page last updated: 2024-12-06

cyamemazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyamemazine: phototoxic neuroleptic effects; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62865
CHEMBL ID2104153
CHEBI ID135379
SCHEMBL ID143041
MeSH IDM0091578

Synonyms (69)

Synonym
rp-7204
gtpl84
10h-phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)-
tercian
f.i. 6229
kyamepromazine
cyamepromazine
10-(3-(dimethylamino)-2-methylpropyl)phenothiazine-2-carbonitrile
cyamemazine [inn]
cianatil
7204 rp
einecs 222-594-2
cyamemazine
brn 0093261
cyamemazin
cyamemazinum [inn-latin]
ciamemazina [inn-spanish]
10-(3-dimethylamino-2-methylpropyl)phenothiazine-2-carbonitrile
th 2602
phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)-
PDSP2_001266
D07307
3546-03-0
cyamemazine (inn)
PDSP1_001282
CHEBI:135379
10-[3-(dimethylamino)-2-methylpropyl]phenothiazine-2-carbonitrile
L001155
FT-0665239
FT-0665240
nsc_62865
cas_62865
bdbm86057
a2jgv5cnu4 ,
4-27-00-04111 (beilstein handbook reference)
fi 6229
ciamemazina
rp 7204
7204 r.e.
unii-a2jgv5cnu4
cyamemazinum
ciamatil
cyamepromezine
10-[3-(dimethylamino)-2-methylpropyl]-10h-phenothiazine-2-carbonitrile
kyamepromazin
fl-6229
th-2602
CHEMBL2104153
cyamemazine [mart.]
cyamemazine [who-dd]
cyamemazine [mi]
SCHEMBL143041
10h-phenothiazine-2-carbonitrile, 10-[3-(dimethylamino)-2-methylpropyl]-
SLFGIOIONGJGRT-UHFFFAOYSA-N
10-[3-(dimethylamino)-2-methylpropyl]-10h-phenothiazine-2-carbonitrile #
DB09000
sr-01000945035
SR-01000945035-1
AKOS030254703
2-cyano-10-(3-[dimethylamino]-2-methyl-propyl)-phenothiazine
cyamemazine, >=98% (hplc)
BCP07169
Q3008033
10-(3-(dimethylamino)-2-methylpropyl)-10h-phenothiazine-2-carbonitrile
HY-14264
CS-0002964
th2602
DTXSID80863190
MS-24809

Research Excerpts

Overview

Cyamemazine (CMZ) is a neuroleptic drug that mediates cutaneous phototoxicity in humans. It is an antipsychotic agent blocking central dopamine D(2) receptors, which induces few extrapyramidal adverse effects, due to a potent antagonistic action at serotonin 5-HT(2A) receptors.

ExcerptReferenceRelevance
"Cyamemazine (CMZ) is a neuroleptic drug that mediates cutaneous phototoxicity in humans. "( Retarded photooxidation of cyamemazine in biomimetic microenvironments.
Jiménez, MC; Limones-Herrero, D; Miranda, MA; Pérez-Ruiz, R,
)
1.87
"Cyamemazine (Tercian®) is an antipsychotic agent blocking central dopamine D(2) receptors, which induces few extrapyramidal adverse effects, due to a potent antagonistic action at serotonin 5-HT(2A) receptors. "( Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
Arbus, C; Benyamina, A; Hodé, Y; Reimold, M, 2011
)
2.27
"Cyamemazine is a neuroleptic D(2)- and 5-HT(2A)-receptor antagonist, with small antagonistic activity at 5-HT(2C) receptors and low incidence of extrapyramidal side effects."( Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine.
Bayle, F; Dib, M; Garay, RP; Hameg, A; Nuss, P; Peinado, J, 2003
)
1.25
"Cyamemazine (Tercian) is an antipsychotic drug with anxiolytic properties. "( A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).
Bayle, F; Demazières, A; Dib, M; Hameg, A; Hodé, Y; Macher, JP; Nuss, P; Reimold, M; Reischl, G, 2005
)
1.98
"Cyamemazine is an original phenothiazine derivative which showed similar efficacy and tolerability to lorazepam during ethanol withdrawal in mice. "( Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome.
Allain, H; Aubin, HJ; Dib, M; Favre, JD; Frija-Orvoen, E; Garcia-Acosta, S; Gillet, C; Kermadi, I; Lejoyeux, M; Payen, A; Weber, M, 2005
)
2.09
"Cyamemazine is an anxiolytic antipsychotic, which reduces ethanol withdrawal symptoms. "( Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome.
Dib, M; Garay, RP; Garcia-Acosta, S; Kermadi, I; Lemoine, P, 2006
)
2.05
"Cyamemazine is a neuroleptic compound which possesses anxiolytic properties in humans. "( 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity.
Alvarez-Guerra, M; d'Alché-Birée, F; Dib, M; Garay, RP; Vargas, F; Wolf, WA, 2000
)
2.01

Toxicity

ExcerptReferenceRelevance
"As part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US FDA Adverse Event Reporting System (FAERS) database to detect signals of torsadogenicity for antipsychotics (APs)."( Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.
Behr, ER; De Ponti, F; Koci, A; Moretti, U; Poluzzi, E; Raschi, E; Spina, E; Sturkenboom, M, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" More than 80% of the cases were described with a dosage of cyamemazine under 100mg/day and no correlation between drug dose and seriousness of the cases were found."( [Cyamemazine (Tercian
Bougerol, T; Khouri, C; Lepelley, M; Mallaret, M; Villier, C, 2017
)
1.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID624215Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A2003Biochemical pharmacology, Feb-01, Volume: 65, Issue:3
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)2003Biochemical pharmacology, Feb-01, Volume: 65, Issue:3
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)2003Biochemical pharmacology, Feb-01, Volume: 65, Issue:3
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2003Biochemical pharmacology, Feb-01, Volume: 65, Issue:3
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2003Biochemical pharmacology, Feb-01, Volume: 65, Issue:3
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
AID624223Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A2003Biochemical pharmacology, Feb-01, Volume: 65, Issue:3
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (7.27)18.7374
1990's9 (16.36)18.2507
2000's22 (40.00)29.6817
2010's18 (32.73)24.3611
2020's2 (3.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.94 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index102.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (6.15%)5.53%
Reviews4 (6.15%)6.00%
Case Studies25 (38.46%)4.05%
Observational0 (0.00%)0.25%
Other32 (49.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]